Exon skipping and aberrant signal peptide cleavage produce novel fibrinogen with an Aα chain lacking the first 42 residues

• References

• 1 Doolittle RF. The molecular biology of fibrin, in Stamatoyannopoulos G. Nienhuis AW, Majerus PW, Varmus H. editors: The Molecular Basis of Blood Diseases. Philadelphia: W. B. Saunders Company; 1994: 701-723.
• 2 Huang S, Cao Z, Chung DW, Davies EW.. The role of βγ and αγ complexes in the assembly of human fibrinogen. J Biol Chem 1996; 271: 27942-27947.
• 3 Brennan SO, Hammonds B, George PM.. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα20 Val→Asp). J Clin Invest 1995; 96: 2854-2858.
• 4 Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121: 1712-1719.
• 5 Hanss M, Biot F.. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90 Available at: http://www.geht.org/databaseang/fibrinogen/
• 6 Asl LH, Liepnieks JJ, Uemichi T. et al. Renal amyloidosis with a frame shift mutation in fibrinogen Aα-chain gene producing a novel amyloid protein. Blood 1997; 90: 4799-4805.
• 7 Gillmore JD, Lachmann HJ, Rowczenio D. et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen Aa-chain amyloidosis. J Am Soc Nephrol 2009; 20: 444-451.
• 8 Brennan SO, Mangos H, Faed J.. Benign FGB (148Lys→Asn, and 448Arg→Lys), and novel causative y211Tyr→His mutation distinguished by time of flight mass spectrometry in a family with hypofibrinogenaemia. Thromb Haemost 2014; 111: 679-684.
• 9 Brennan SO, Laurie AD, Mo A. et al. Novel fibrinogen mutations (Aα17Gly→Cys and Aα381Ser→Phe) occurring with a 312Thr→Ala polymorphism; allelic phase assigned by direct mass measurement. Blood Coagul Fibrinol 2015; 26: 882-886.
• 10 Brennan SO, Laurie A, Smith M.. Novel FGG variant (γ339C→S) confirms importance of the γ326–339 disulphide bond for plasma expression of newly synthesised fibrinogen. Thromb Haemost 2015; 113: 903-905.
• 11 Maghzal GJ, Brennan SO, Homer VM. et al. The molecular mechanisms of congenital hypofibrinogenaemia. Cellular and Molecular Life Sciences. 2004; 61: 1427-1438.
• 12 Emanuelsson O, Brunak S, von Heijne G. et al. Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc 2007; 2: 953-971.
• 13 Brennan SO, Myles T., Peach RJ. et al. Albumin Redhill (-1 Arg, 320 Ala→Thr). A glycoprotein variant of human albumin whose precursor has an aberrant signal peptide cleavage site. Proc Natl Acad Sci USA 1990; 87: 26-30.
• 14 Vorjohann S, Fish RJ, Biron-Andreani C. et al. Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A’. Thromb Haemost 2010; 104: 990-997.
• 15 Hanss M, Biot F.. A database for human fibrinogen variants. Ann NY Acad Sci 2001; 936: 89-90 Available at: http://www.geht.org/databaseang/fibrinogen/
• 16 Neerman-Arbez M, de Moerloose P.. Mutations in the fibrinogen gene cluster account for congenital afibrinogenaemia: an update and report of 10 novel mutations. Hum Mutat 2007; 28: 540-553.
• 17 Zhang J-Z, Redman C.. Fibrinogen assembly and secretion; role of intrachain disulphide loops. J Biol Chem 1996; 271: 30083-30088.
• 18 Hanss M, Pouymayou C, Blouch M-T. et al. The natural occurrence of human fibrinogen variants disrupting inter-chain disulfide bonds (AαCys36Gly, AαCys36Arg and AαCys45Tyr) confirms the role of N-terminal Aa disulfide bonds in protein assembly and secretion. Haematologica 2011; 96: 1226-1230.